Skip to content
Study details
Enrolling now

Suvorexant and Alcohol

William Stoops
NCT IDNCT06326684ClinicalTrials.gov data as of Apr 2026
Phase

EARLY_PHASE1

Target enrollment

30

Study length

about 2.8 years

Ages

21–55

Locations

1 site in KY

What this study is about

This trial is testing whether suvorexant, a medication, helps reduce alcohol cravings and other related behaviors in people with Alcohol Use Disorder. The goal is to understand how orexin affects alcohol addiction in humans. This research will provide initial clinical evidence on the effects of orexin antagonism on alcohol motivation.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Alcohol
  • 2.Take Placebo
  • 3.Take Suvorexant

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Oral

How treatment is administered

Treatment Assignment
Randomized & Blinded

You may get a placebo/standard care, and you won't know which.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

ethanol, suvorexant

Drug routes

oral (Oral Tablet)

Endpoints

Secondary: Blood pressure, Heart rate, Mood

Body systems

Psychiatry / Mental Health